Dendreon Raises $230 Million To Fund Filing And Anticipated Launch Of Provenge
This article was originally published in The Pink Sheet Daily
Executive Summary
With strong overall survival data in hand for its prostate cancer vaccine, Seattle biotech takes advantage of increased investor interest.